Chemotherapy-Induced Nausea and Vomiting Prophylaxis
The ASCO guideline provides updated recommendations for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) based on the emetic risk of the treatment regimen.
Oncology
FDA-Approved Biosimilars
A comparative list of biosimilars approved by the FDA including their reference products, dosage forms and indications.
FDA-Approved Prostate Cancer Treatments
Approved prostate cancer drug treatments including formulations and usual dosing.
FDA-Approved Ovarian Cancer Treatments
FDA-Approved treatment options for individuals with ovarian cancer including dosing.
FDA-Approved Breast Cancer Treatments
FDA-approved oral and injectable treatment options for breast cancer.
Acute Myeloid Leukemia: Type of Anthracycline May Not Affect Long-Term Outcomes
Among patients with AML, the type of anthracycline received, and whether some patients undergoing stem cell transplantation have an HLA-identical donor, may not affect long-term outcomes.
FDA Approves Reblozyl for Anemia in Patients With Myelodysplastic Syndromes
The FDA has approved Reblozyl® (luspatercept–aamt; Bristol-Myers Squibb and Acceleron) for the treatment of anemia in adults with lower-risk myelodysplastic syndromes.
FDA-Approved Non-Small Cell Lung Cancer (NSCLC) Treatments
Chemotherapeutic and biologic agents for the treatment of non-small cell lung cancer (NSCLC).
Emetogenic Potential of Antineoplastic Agents
Emetogenic potential (high, moderate, low, or minimal risk) of oral and injectable antineoplastic agents.
